search
Back to results

A Randomised Study Evaluating Diagnostics of Pleural Effusion Among Patients Suspect of Cancer.

Primary Purpose

Pleural Effusion, Malignant, Pleural Effusion, Pleura; Exudate

Status
Terminated
Phase
Not Applicable
Locations
Denmark
Study Type
Interventional
Intervention
Local anesthetic thoracoscopy
US-guided pleural biopsy
Sponsored by
Naestved Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional diagnostic trial for Pleural Effusion, Malignant focused on measuring Pleural effusion, Malignant Pleural effusion, Pleura diagnostics, US-guided pleural biopsy, Local anesthetic thoracoscopy

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Age 18 years or older patients with single previous thoracentesis of a unilateral pleural exudate according to Lights criteria without malignant cells.
  • Lights Criteria:

Pleural fluid protein/serum protein ratio greater than 0.5 pleural fluid LDH/serum LDH ratio greater than 0.6 Pleural fluid LDH greater than two-thirds the upper limits of the Laboratorys normal Serum LDH

  • Contrast enhanced CT of the Chest and abdomen performed
  • Clinical suspicion of cancer such as, but not limited to, weight loss, malaise, anemia
  • Pet-CT results or former cancer diagnosis Informed consent

Exclusion Criteria:

  • bilateral pleural effusions
  • known cause of pleural effusion
  • likely non-malignant course of a unilateral pleura effusion such as (but not restricted to) pneumonia, trauma, pleuritis, heart failure
  • any contraindication to the study procedures

Sites / Locations

  • Næstved Hospital
  • University Hospital Zealand, Roskilde

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Experimental

Arm Label

US-guided pleural biopsy and thoracentesis

LAT and thoracentesis

Arm Description

Pleural biopsy: Using ultrasound the optimal point of entry for thoracentesis is located, and local anesthesia is obtained. The area is wiped with disinfectant and a skin incision is made with a pointed scalpel. Six US-guided biopsies of 1x2 millimetres are taken from the parietal pleura using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core Biopsy Needle 18G, Tempe, Arizona, USA). Afterward, a thoracentesis is performed in the same incision as used by the pleural biopsy. A pigtail catheter is inserted and fastened and connected to a sealed bag and fluid is aspirated and sent to relevant analysis.

Local anesthetic thoracoscopy: Pre-procedure a pleural pigtail catheter is inserted and pleural fluid is removed. The catheters one-way valve is opened and the patient takes several breaths thereby creating a pneumothorax prior to procedure start. The patient is sedated with midazolam and morphine. Midaxillary access through intercostal space 4-7 is achieved in local anesthesia and via a skin incision a trocar is placed for access to the thoracic space. A semi-rigid thoracoscope (model LTF 160; Olympus, Tokyo, Japan) is inserted via the trocar and the pleural cavity is inspected after removal of residual effusion whereof at least 40ml is sent to cytology. Pleural parietal biopsies are taken under direct visual guidance. The recommended number of biopsies is 10-15. If no abnormalities were seen, random biopsies are taken. After relevant biopsies are taken the instruments are removed the pigtail catheter stays inserted to allow for removal of air and expansion of the lung.

Outcomes

Primary Outcome Measures

Incidence of treatment-guiding pleural workup to provide and plan treatment for the cause of the pleura exudate, local anesthetic thoracoscopy vs 2. thoracentesis
Difference in incidence of treatment-guiding diagnostic workup in local anesthetic thoracoscopy versus 2nd thoracentesis
Incidence of treatment-guiding pleural workup to provide and plan treatment for the cause of the pleura exudate. Local anesthetic thoracoscopy vs US-guided pleural biopsy.
Difference in incidence of treatment-guiding diagnostic workup in local anesthetic thoracoscopy versus US-guided pleural biopsy prior to 2nd thoracentesis

Secondary Outcome Measures

Incidence of achieving pleural immunohistochemistry, mutations, oncodrivers, culture and biochemistry.
Incidence of completed procedures
Time from randomization to conclusive, treatment-guiding diagnoses
Time from start of consultation with medical staff until end of consultation with medical staff on the day of the procedure
Time from procedure start to patient leaving the procedure room and leaving the recovery room
Adverse event; complication to procedure: mortality
Evaluated on day of procedure, 7 days and 30 days. The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
Adverse event; complication to procedure: pneumothorax
Evaluated on day of procedure, 7 days and 30 days. The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
Adverse event; complication to procedure: haemoptysis
Evaluated on day of procedure, 7 days and 30 days. The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
Adverse event; complication to procedure: infection
Evaluated on day of procedure, 7 days and 30 days. The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
Adverse event; complication to procedure: hospital admission
Evaluated on day of procedure, 7 days and 30 days. The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
Total volume of pleural fluid removed
In mililiter (ml)
Patient reported discomfort reported via ESAS
ESAS - Edmonton Symptom Assesment System, Danish Version 2008
Patient reported discomfort reported via EQ-5D-5L
Denmark (Danish) © 2009 EuroQol Group EQ-5D™
Willingness to repeat procedure
5 Point Likert Scale, 1 not likely to repeat, 5 most likely to repeat
Cough
Visual analogue scale 1-10. 1 Being no cough, 10 being extreme cough

Full Information

First Posted
January 15, 2020
Last Updated
September 24, 2020
Sponsor
Naestved Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04233359
Brief Title
A Randomised Study Evaluating Diagnostics of Pleural Effusion Among Patients Suspect of Cancer.
Official Title
Local Anesthetic Thoracoscopy Versus Ultrasound Guided Pleural Biopsies and Repeat Thoracocentesis in Pleural Effusion After Inconclusive Initial Thoracentesis: a Randomized Study
Study Type
Interventional

2. Study Status

Record Verification Date
September 2020
Overall Recruitment Status
Terminated
Why Stopped
To few patients recruited to allow for study completion within ph.d. project.
Study Start Date
December 20, 2019 (Actual)
Primary Completion Date
September 24, 2020 (Actual)
Study Completion Date
September 24, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Naestved Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Pleural fluid can be caused by cancer. Patients with repeated presentation of pleural fluid where initial diagnostic tests have been inconclusive are the focus of this trial. In this clinical trial patients are randomized into two groups and the efficacy of local anesthetic thoracoscopy (LAT) is compared to an ultrasound guided biopsy of the outer lining of the lung. The aim is not only the diagnostic yield in diagnosing cancer, but also the procedures ability to diagnose specific cancer mutations and immune system markings. Methods and objectives: Patients with reoccuring one-sided pleural fluid, with a marked clinical risk of cancer based on findings in medical work-up, radiological scans, biochemistry and medical history and who are undiagnosed upon initial pleural fluid analysis are the target patients of the trial. Patients are randomized into two groups to have undertaken either pleural biopsy at the optimal site for a repeat thoracentesis or LAT. Thus diagnostic yield for both fluid analysis and biopsy analysis will be compared to tissue samples taken with LAT. We hypothesize that LAT is superior both to pleural biopsy and repeat thoracentesis in providing diagnostic clarification and providing sufficient basis for treatment without further procedures resulting in less time consumption, cost and discomfort for the patient.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pleural Effusion, Malignant, Pleural Effusion, Pleura; Exudate
Keywords
Pleural effusion, Malignant Pleural effusion, Pleura diagnostics, US-guided pleural biopsy, Local anesthetic thoracoscopy

7. Study Design

Primary Purpose
Diagnostic
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
4 (Actual)

8. Arms, Groups, and Interventions

Arm Title
US-guided pleural biopsy and thoracentesis
Arm Type
Active Comparator
Arm Description
Pleural biopsy: Using ultrasound the optimal point of entry for thoracentesis is located, and local anesthesia is obtained. The area is wiped with disinfectant and a skin incision is made with a pointed scalpel. Six US-guided biopsies of 1x2 millimetres are taken from the parietal pleura using closed needle biopsies (Quick-core Biopsy Needle 18G, COOK Medical, Bloomington, Indiana, USA or Bard Max Core Biopsy Needle 18G, Tempe, Arizona, USA). Afterward, a thoracentesis is performed in the same incision as used by the pleural biopsy. A pigtail catheter is inserted and fastened and connected to a sealed bag and fluid is aspirated and sent to relevant analysis.
Arm Title
LAT and thoracentesis
Arm Type
Experimental
Arm Description
Local anesthetic thoracoscopy: Pre-procedure a pleural pigtail catheter is inserted and pleural fluid is removed. The catheters one-way valve is opened and the patient takes several breaths thereby creating a pneumothorax prior to procedure start. The patient is sedated with midazolam and morphine. Midaxillary access through intercostal space 4-7 is achieved in local anesthesia and via a skin incision a trocar is placed for access to the thoracic space. A semi-rigid thoracoscope (model LTF 160; Olympus, Tokyo, Japan) is inserted via the trocar and the pleural cavity is inspected after removal of residual effusion whereof at least 40ml is sent to cytology. Pleural parietal biopsies are taken under direct visual guidance. The recommended number of biopsies is 10-15. If no abnormalities were seen, random biopsies are taken. After relevant biopsies are taken the instruments are removed the pigtail catheter stays inserted to allow for removal of air and expansion of the lung.
Intervention Type
Procedure
Intervention Name(s)
Local anesthetic thoracoscopy
Other Intervention Name(s)
medical thoracoscopy
Intervention Description
Procedure to obtain histological biopsies of the parietal pleura on awake, fastening patients.
Intervention Type
Procedure
Intervention Name(s)
US-guided pleural biopsy
Intervention Description
In local anesthesia, a closed needle biopsy is performed Ultrasound guided of the parietal pleura at the place of deepest fluid recess in the intrathoracic space. A pigtail catheter French 7-16 is placed afterwards for fluid drainage.
Primary Outcome Measure Information:
Title
Incidence of treatment-guiding pleural workup to provide and plan treatment for the cause of the pleura exudate, local anesthetic thoracoscopy vs 2. thoracentesis
Description
Difference in incidence of treatment-guiding diagnostic workup in local anesthetic thoracoscopy versus 2nd thoracentesis
Time Frame
26 weeks
Title
Incidence of treatment-guiding pleural workup to provide and plan treatment for the cause of the pleura exudate. Local anesthetic thoracoscopy vs US-guided pleural biopsy.
Description
Difference in incidence of treatment-guiding diagnostic workup in local anesthetic thoracoscopy versus US-guided pleural biopsy prior to 2nd thoracentesis
Time Frame
26 weeks
Secondary Outcome Measure Information:
Title
Incidence of achieving pleural immunohistochemistry, mutations, oncodrivers, culture and biochemistry.
Time Frame
26 weeks
Title
Incidence of completed procedures
Time Frame
1 week
Title
Time from randomization to conclusive, treatment-guiding diagnoses
Time Frame
26 weeks
Title
Time from start of consultation with medical staff until end of consultation with medical staff on the day of the procedure
Time Frame
Day of procedure/intervention
Title
Time from procedure start to patient leaving the procedure room and leaving the recovery room
Time Frame
Day of procedure/intervention
Title
Adverse event; complication to procedure: mortality
Description
Evaluated on day of procedure, 7 days and 30 days. The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
Time Frame
30 days.
Title
Adverse event; complication to procedure: pneumothorax
Description
Evaluated on day of procedure, 7 days and 30 days. The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
Time Frame
30 days.
Title
Adverse event; complication to procedure: haemoptysis
Description
Evaluated on day of procedure, 7 days and 30 days. The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
Time Frame
30 days.
Title
Adverse event; complication to procedure: infection
Description
Evaluated on day of procedure, 7 days and 30 days. The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
Time Frame
30 days.
Title
Adverse event; complication to procedure: hospital admission
Description
Evaluated on day of procedure, 7 days and 30 days. The 2 last are performed via telephone call to the patient and informations gathering in the electronic patient file system
Time Frame
30 days.
Title
Total volume of pleural fluid removed
Description
In mililiter (ml)
Time Frame
Day of procedure
Title
Patient reported discomfort reported via ESAS
Description
ESAS - Edmonton Symptom Assesment System, Danish Version 2008
Time Frame
Day of procedure pre- and post-procedure and 1 week followup
Title
Patient reported discomfort reported via EQ-5D-5L
Description
Denmark (Danish) © 2009 EuroQol Group EQ-5D™
Time Frame
Day of procedure pre- and post-proceudre and 1 week followup
Title
Willingness to repeat procedure
Description
5 Point Likert Scale, 1 not likely to repeat, 5 most likely to repeat
Time Frame
After procedure performed - within 30 minutes and 1 week after proceudre
Title
Cough
Description
Visual analogue scale 1-10. 1 Being no cough, 10 being extreme cough
Time Frame
Pre-procedure, 1 week post procedure.

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age 18 years or older patients with single previous thoracentesis of a unilateral pleural exudate according to Lights criteria without malignant cells. Lights Criteria: Pleural fluid protein/serum protein ratio greater than 0.5 pleural fluid LDH/serum LDH ratio greater than 0.6 Pleural fluid LDH greater than two-thirds the upper limits of the Laboratorys normal Serum LDH Contrast enhanced CT of the Chest and abdomen performed Clinical suspicion of cancer such as, but not limited to, weight loss, malaise, anemia Pet-CT results or former cancer diagnosis Informed consent Exclusion Criteria: bilateral pleural effusions known cause of pleural effusion likely non-malignant course of a unilateral pleura effusion such as (but not restricted to) pneumonia, trauma, pleuritis, heart failure any contraindication to the study procedures
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Uffe Bødtger, MD ph.d.
Organizational Affiliation
Næstved
Official's Role
Study Chair
Facility Information:
Facility Name
Næstved Hospital
City
Næstved
ZIP/Postal Code
4700
Country
Denmark
Facility Name
University Hospital Zealand, Roskilde
City
Roskilde
ZIP/Postal Code
4000
Country
Denmark

12. IPD Sharing Statement

Plan to Share IPD
No
Citations:
PubMed Identifier
1493651
Citation
Saks AM, Posner R. Tuberculosis in HIV positive patients in South Africa: a comparative radiological study with HIV negative patients. Clin Radiol. 1992 Dec;46(6):387-90. doi: 10.1016/s0009-9260(05)80684-1.
Results Reference
background
PubMed Identifier
30262573
Citation
Arnold DT, De Fonseka D, Perry S, Morley A, Harvey JE, Medford A, Brett M, Maskell NA. Investigating unilateral pleural effusions: the role of cytology. Eur Respir J. 2018 Nov 8;52(5):1801254. doi: 10.1183/13993003.01254-2018. Print 2018 Nov.
Results Reference
background
PubMed Identifier
24360987
Citation
Porcel JM, Esquerda A, Vives M, Bielsa S. Etiology of pleural effusions: analysis of more than 3,000 consecutive thoracenteses. Arch Bronconeumol. 2014 May;50(5):161-5. doi: 10.1016/j.arbres.2013.11.007. Epub 2013 Dec 20. English, Spanish.
Results Reference
background
PubMed Identifier
8222812
Citation
Marel M, Zrustova M, Stasny B, Light RW. The incidence of pleural effusion in a well-defined region. Epidemiologic study in central Bohemia. Chest. 1993 Nov;104(5):1486-9. doi: 10.1378/chest.104.5.1486.
Results Reference
background
PubMed Identifier
27581830
Citation
Bintcliffe OJ, Lee GY, Rahman NM, Maskell NA. The management of benign non-infective pleural effusions. Eur Respir Rev. 2016 Sep;25(141):303-16. doi: 10.1183/16000617.0026-2016.
Results Reference
background
PubMed Identifier
20696692
Citation
Hooper C, Lee YC, Maskell N; BTS Pleural Guideline Group. Investigation of a unilateral pleural effusion in adults: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 Aug;65 Suppl 2:ii4-17. doi: 10.1136/thx.2010.136978. No abstract available.
Results Reference
background
PubMed Identifier
25706291
Citation
Porcel JM, Gasol A, Bielsa S, Civit C, Light RW, Salud A. Clinical features and survival of lung cancer patients with pleural effusions. Respirology. 2015 May;20(4):654-9. doi: 10.1111/resp.12496. Epub 2015 Feb 23.
Results Reference
background
PubMed Identifier
20696691
Citation
Roberts ME, Neville E, Berrisford RG, Antunes G, Ali NJ; BTS Pleural Disease Guideline Group. Management of a malignant pleural effusion: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 Aug;65 Suppl 2:ii32-40. doi: 10.1136/thx.2010.136994. No abstract available.
Results Reference
background
PubMed Identifier
19670115
Citation
Orki A, Akin O, Tasci AE, Ciftci H, Urek S, Falay O, Kutlu CA. The role of positron emission tomography/computed tomography in the diagnosis of pleural diseases. Thorac Cardiovasc Surg. 2009 Jun;57(4):217-21. doi: 10.1055/s-2008-1039314. Epub 2009 May 20.
Results Reference
background
PubMed Identifier
9494600
Citation
Naito T, Satoh H, Ishikawa H, Yamashita YT, Kamma H, Takahashi H, Ohtsuka M, Hasegawa S. Pleural effusion as a significant prognostic factor in non-small cell lung cancer. Anticancer Res. 1997 Nov-Dec;17(6D):4743-6.
Results Reference
background
PubMed Identifier
2068057
Citation
Nance KV, Shermer RW, Askin FB. Diagnostic efficacy of pleural biopsy as compared with that of pleural fluid examination. Mod Pathol. 1991 May;4(3):320-4.
Results Reference
background
PubMed Identifier
8112449
Citation
Loddenkemper R, Boutin C. Thoracoscopy: present diagnostic and therapeutic indications. Eur Respir J. 1993 Nov;6(10):1544-55.
Results Reference
background
PubMed Identifier
7991525
Citation
Garcia LW, Ducatman BS, Wang HH. The value of multiple fluid specimens in the cytological diagnosis of malignancy. Mod Pathol. 1994 Aug;7(6):665-8.
Results Reference
background
PubMed Identifier
25997433
Citation
Koegelenberg CF, Irusen EM, von Groote-Bidlingmaier F, Bruwer JW, Batubara EM, Diacon AH. The utility of ultrasound-guided thoracentesis and pleural biopsy in undiagnosed pleural exudates. Thorax. 2015 Oct;70(10):995-7. doi: 10.1136/thoraxjnl-2014-206567. Epub 2015 May 21.
Results Reference
background
PubMed Identifier
4642731
Citation
Light RW, Macgregor MI, Luchsinger PC, Ball WC Jr. Pleural effusions: the diagnostic separation of transudates and exudates. Ann Intern Med. 1972 Oct;77(4):507-13. doi: 10.7326/0003-4819-77-4-507. No abstract available.
Results Reference
background
PubMed Identifier
30625466
Citation
Amiri Z, Momtahan M, Mokhtari M. Comparison of Conventional Cytology, Liquid-Based Cytology, and Cell Block in the Evaluation of Peritoneal Fluid in Gynecology Malignancies. Acta Cytol. 2019;63(1):63-72. doi: 10.1159/000495571. Epub 2019 Jan 9.
Results Reference
background
PubMed Identifier
31209979
Citation
Pak MG, Roh MS. Cell-blocks are suitable material for programmed cell death ligand-1 immunohistochemistry: Comparison of cell-blocks and matched surgical resection specimens in lung cancer. Cytopathology. 2019 Nov;30(6):578-585. doi: 10.1111/cyt.12743. Epub 2019 Jul 19.
Results Reference
background
PubMed Identifier
26779911
Citation
Metintas M, Yildirim H, Kaya T, Ak G, Dundar E, Ozkan R, Metintas S. CT Scan-Guided Abrams' Needle Pleural Biopsy versus Ultrasound-Assisted Cutting Needle Pleural Biopsy for Diagnosis in Patients with Pleural Effusion: A Randomized, Controlled Trial. Respiration. 2016;91(2):156-63. doi: 10.1159/000443483. Epub 2016 Jan 19.
Results Reference
background
PubMed Identifier
24832701
Citation
Hallifax RJ, Corcoran JP, Ahmed A, Nagendran M, Rostom H, Hassan N, Maruthappu M, Psallidas I, Manuel A, Gleeson FV, Rahman NM. Physician-based ultrasound-guided biopsy for diagnosing pleural disease. Chest. 2014 Oct;146(4):1001-1006. doi: 10.1378/chest.14-0299.
Results Reference
background
PubMed Identifier
27454475
Citation
Laursen CB, Naur TM, Bodtger U, Colella S, Naqibullah M, Minddal V, Konge L, Davidsen JR, Hansen NC, Graumann O, Clementsen PF. Ultrasound-guided Lung Biopsy in the Hands of Respiratory Physicians: Diagnostic Yield and Complications in 215 Consecutive Patients in 3 Centers. J Bronchology Interv Pulmonol. 2016 Jul;23(3):220-8. doi: 10.1097/LBR.0000000000000297.
Results Reference
background
PubMed Identifier
30060030
Citation
Bibby AC, Dorn P, Psallidas I, Porcel JM, Janssen J, Froudarakis M, Subotic D, Astoul P, Licht P, Schmid R, Scherpereel A, Rahman NM, Maskell NA, Cardillo G. ERS/EACTS statement on the management of malignant pleural effusions. Eur J Cardiothorac Surg. 2019 Jan 1;55(1):116-132. doi: 10.1093/ejcts/ezy258.
Results Reference
background
PubMed Identifier
30272503
Citation
Feller-Kopman DJ, Reddy CB, DeCamp MM, Diekemper RL, Gould MK, Henry T, Iyer NP, Lee YCG, Lewis SZ, Maskell NA, Rahman NM, Sterman DH, Wahidi MM, Balekian AA. Management of Malignant Pleural Effusions. An Official ATS/STS/STR Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Oct 1;198(7):839-849. doi: 10.1164/rccm.201807-1415ST.
Results Reference
background
PubMed Identifier
24992129
Citation
Willendrup F, Bodtger U, Colella S, Rasmussen D, Clementsen PF. Diagnostic accuracy and safety of semirigid thoracoscopy in exudative pleural effusions in Denmark. J Bronchology Interv Pulmonol. 2014 Jul;21(3):215-9. doi: 10.1097/LBR.0000000000000088.
Results Reference
background
PubMed Identifier
23418922
Citation
Rozman A, Camlek L, Marc-Malovrh M, Triller N, Kern I. Rigid versus semi-rigid thoracoscopy for the diagnosis of pleural disease: a randomized pilot study. Respirology. 2013 May;18(4):704-10. doi: 10.1111/resp.12066.
Results Reference
background
PubMed Identifier
24106326
Citation
Dhooria S, Singh N, Aggarwal AN, Gupta D, Agarwal R. A randomized trial comparing the diagnostic yield of rigid and semirigid thoracoscopy in undiagnosed pleural effusions. Respir Care. 2014 May;59(5):756-64. doi: 10.4187/respcare.02738. Epub 2013 Oct 8.
Results Reference
background
PubMed Identifier
20696694
Citation
Rahman NM, Ali NJ, Brown G, Chapman SJ, Davies RJ, Downer NJ, Gleeson FV, Howes TQ, Treasure T, Singh S, Phillips GD; British Thoracic Society Pleural Disease Guideline Group. Local anaesthetic thoracoscopy: British Thoracic Society Pleural Disease Guideline 2010. Thorax. 2010 Aug;65 Suppl 2:ii54-60. doi: 10.1136/thx.2010.137018. No abstract available.
Results Reference
background
PubMed Identifier
9042652
Citation
Light RW. Diagnostic principles in pleural disease. Eur Respir J. 1997 Feb;10(2):476-81. doi: 10.1183/09031936.97.10020476.
Results Reference
background
PubMed Identifier
20154079
Citation
Metintas M, Ak G, Dundar E, Yildirim H, Ozkan R, Kurt E, Erginel S, Alatas F, Metintas S. Medical thoracoscopy vs CT scan-guided Abrams pleural needle biopsy for diagnosis of patients with pleural effusions: a randomized, controlled trial. Chest. 2010 Jun;137(6):1362-8. doi: 10.1378/chest.09-0884. Epub 2010 Feb 12.
Results Reference
background
PubMed Identifier
19741064
Citation
Swiderek J, Morcos S, Donthireddy V, Surapaneni R, Jackson-Thompson V, Schultz L, Kini S, Kvale P. Prospective study to determine the volume of pleural fluid required to diagnose malignancy. Chest. 2010 Jan;137(1):68-73. doi: 10.1378/chest.09-0641. Epub 2009 Sep 9.
Results Reference
background
PubMed Identifier
19017891
Citation
Abouzgheib W, Bartter T, Dagher H, Pratter M, Klump W. A prospective study of the volume of pleural fluid required for accurate diagnosis of malignant pleural effusion. Chest. 2009 Apr;135(4):999-1001. doi: 10.1378/chest.08-2002. Epub 2008 Nov 18.
Results Reference
background

Learn more about this trial

A Randomised Study Evaluating Diagnostics of Pleural Effusion Among Patients Suspect of Cancer.

We'll reach out to this number within 24 hrs